{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-10-06T10:43:26Z", "providers": [ "Claude" ], "breadth": "written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify", "pass": 2, "wave": 23, "engine": "claude", "gate": { "passed": true, "version": "1.0", "at": "2026-10-09T07:29:58+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q1023650", "registryId": "vr.tr.chop", "name": "CHOP", "version": "0.2.0-wave.23", "entryKind": "thing", "family": "Thing Registry", "domain": [ "ACT.PRC" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q1023650/", "model": { "registry_id": "vr.tr.chop", "name": "CHOP", "purpose": "Let an agent explain what the CHOP regimen is, what its letters stand for and where it fits in lymphoma treatment, at the level of reference material, while leaving dosing, scheduling and treatment decisions to the oncology team.", "definition": "CHOP is a combination chemotherapy regimen named for its four components - cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine and prednisone - used mainly to treat non-Hodgkin lymphoma, and commonly given with the antibody rituximab as R-CHOP.", "what_it_is_for": "Treating non-Hodgkin lymphoma and some related cancers by combining drugs with different mechanisms.", "affordances": [ "expand the acronym into its component drugs", "explain the role of the regimen in lymphoma care", "distinguish CHOP from R-CHOP and other variants", "relay commonly reported side effects at reference level", "point a patient to their treating team for decisions" ], "distinguishing_features": [ "Four named drugs, one per letter", "R-CHOP adds rituximab and is a distinct regimen record", "CHOP-like variants swap or add drugs and carry other acronyms", "A regimen is a treatment protocol, not a drug or a disease" ], "appearance": null, "visual_identification": [ "Named in clinical records as CHOP, R-CHOP or a lettered variant", "A cyclic course combining an alkylating agent, an anthracycline, a vinca alkaloid and a corticosteroid" ], "physical_properties": [ { "quantity": "kind", "typical_range": "combination chemotherapy regimen", "unit": "note", "note": "" }, { "quantity": "components", "typical_range": "cyclophosphamide, doxorubicin, vincristine, prednisone", "unit": "note", "note": "" }, { "quantity": "delivery", "typical_range": "repeated cycles, mostly intravenous with an oral steroid", "unit": "note", "note": "" } ], "families_and_kinds": [ "CHOP", "R-CHOP", "CHOP-14 and CHOP-21 schedules", "CHOEP and other modified CHOP regimens" ], "related_models": [ { "relation": "is a kind of", "target": "combination chemotherapy regimen", "why": "" }, { "relation": "contains", "target": "cyclophosphamide", "why": "the C" }, { "relation": "contains", "target": "doxorubicin", "why": "the H, from hydroxydaunorubicin" }, { "relation": "contains", "target": "vincristine", "why": "the O" }, { "relation": "contains", "target": "prednisone", "why": "the P" }, { "relation": "needs", "target": "non-Hodgkin lymphoma", "why": "its main indication" } ], "identifiers": [ { "scheme": "Wikidata", "value_or_pattern": "Q1023650", "note": "registry item" } ], "standards_and_regulation": [ "Clinical practice guidelines for lymphoma issued by national and professional oncology bodies", "Marketing authorisations of each component drug by medicines regulators", "Hospital chemotherapy protocols and safe handling rules for cytotoxic drugs" ], "failure_modes_and_hazards": [ "Serious side effects including low blood counts and infection risk", "Cumulative heart toxicity associated with anthracyclines", "Nerve damage associated with vincristine", "Confusing CHOP with R-CHOP or with an unrelated acronym" ], "agent_conduct": { "may": [ "Explain the regimen and its components at reference level and cite the guideline used.", "Help a patient prepare questions for their oncology team." ], "must_not": [ "Give doses, cycle schedules or dose adjustments.", "Advise starting, stopping or changing treatment.", "Present the regimen as right for a particular patient.", "Disclose a person's treatment details without consent." ], "requires_human": [ "Any decision to prescribe, give, modify or stop the regimen." ] }, "ethics": { "considerations": [ "Patients face hard trade-offs between cure rates and toxicity and need honest information.", "Treatment records are sensitive health data." ], "affected_parties": [ "Patients with lymphoma", "Their families and carers", "Oncology staff handling cytotoxic drugs" ] }, "owners": { "steward": "Nobody owns the regimen; the treating oncology team answers for its use in a given patient.", "master_systems": [ "Clinical guidelines", "Hospital chemotherapy protocol libraries", "Patient medical records" ] }, "in_scope": [], "out_of_scope": [], "characteristics": [] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q1023650: CHOP", "url": "https://www.wikidata.org/wiki/Q1023650", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: CHOP (chemotherapy)", "url": "https://en.wikipedia.org/wiki/CHOP_%28chemotherapy%29", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "composition", "name": "Composition", "description": "What the regimen contains.", "rationale": "The acronym is the regimen's identity and is often misread.", "layers": [ { "id": "components", "name": "Components", "description": "The four drugs.", "findings": [ { "id": "components-finding", "name": "Components", "description": "The four drugs.", "questions": [ { "text": "Which drug does each letter of CHOP stand for?", "kind": "definition" }, { "text": "What class of drug is each component?", "kind": "definition" } ] } ] }, { "id": "variants", "name": "Variants", "description": "R-CHOP and modified regimens.", "findings": [ { "id": "variants-finding", "name": "Variants", "description": "R-CHOP and modified regimens.", "questions": [ { "text": "How does R-CHOP differ from CHOP, and which is meant in a given record?", "kind": "boundary" }, { "text": "Which modified CHOP regimens exist and what do they change?", "kind": "provenance" } ] } ] } ] }, { "id": "indication", "name": "Indication", "description": "Where it is used.", "rationale": "A regimen is defined by the disease it is used for.", "layers": [ { "id": "lymphoma", "name": "Lymphoma", "description": "Non-Hodgkin lymphoma subtypes.", "findings": [ { "id": "lymphoma-finding", "name": "Lymphoma", "description": "Non-Hodgkin lymphoma subtypes.", "questions": [ { "text": "For which lymphoma subtypes do guidelines recommend CHOP or R-CHOP?", "kind": "provenance" }, { "text": "Which guideline and version supports the statement?", "kind": "provenance" } ] } ] }, { "id": "history", "name": "History", "description": "Place in the history of treatment.", "findings": [ { "id": "history-finding", "name": "History", "description": "Place in the history of treatment.", "questions": [ { "text": "When was CHOP introduced and how did it become a standard?", "kind": "provenance" }, { "text": "What changed when rituximab was added?", "kind": "provenance" } ] } ] } ] }, { "id": "safety", "name": "Safety", "description": "Side effects and risks.", "rationale": "Toxicity is what patients most often ask about.", "layers": [ { "id": "toxicity", "name": "Toxicity", "description": "Known adverse effects.", "findings": [ { "id": "toxicity-finding", "name": "Toxicity", "description": "Known adverse effects.", "questions": [ { "text": "Which side effects are commonly reported for the regimen?", "kind": "provenance" }, { "text": "Which effects are linked to which component?", "kind": "boundary" } ] } ] }, { "id": "monitoring", "name": "Monitoring", "description": "What is checked during treatment.", "findings": [ { "id": "monitoring-finding", "name": "Monitoring", "description": "What is checked during treatment.", "questions": [ { "text": "What kinds of monitoring do guidelines describe during treatment?", "kind": "measurement" }, { "text": "Who decides when results require a change?", "kind": "action" } ] } ] } ] }, { "id": "conduct", "name": "Conduct", "description": "How an agent may discuss it.", "rationale": "Questions about a regimen easily become requests for medical advice.", "layers": [ { "id": "scope", "name": "Scope", "description": "Reference versus advice.", "findings": [ { "id": "scope-finding", "name": "Scope", "description": "Reference versus advice.", "questions": [ { "text": "Is the request for general information or about a specific patient?", "kind": "boundary" }, { "text": "Which questions must be referred to the treating team?", "kind": "action" } ] } ] }, { "id": "privacy", "name": "Privacy", "description": "Treatment records.", "findings": [ { "id": "privacy-finding", "name": "Privacy", "description": "Treatment records.", "questions": [ { "text": "Does the request involve a named person's treatment data?", "kind": "boundary" }, { "text": "Is consent in place to discuss it?", "kind": "action" } ] } ] } ] } ] }, "openQuestions": [ "Should R-CHOP be a separate entry linked to this one?", "How should guideline versions be tracked as recommendations change?", "Should CHOP schedule variants be modelled as kinds or as attributes?" ], "statistics": { "bundles": 4, "layers": 8, "findings": 8, "questions": 16 } }